The online market for compounded semaglutide and other peptides has grown into a massive, loosely regulated ecosystem. If you have looked into getting semaglutide without paying brand-name prices (or without insurance coverage), you have probably encountered websites offering "compounded semaglutide" at a fraction of the cost. Some of these operations are legitimate compounding pharmacies. Some are not. And telling the difference requires understanding a regulatory framework that most people, including many prescribers, do not fully grasp. This article is not here to tell you what to do. It is here to lay out what is actually known about the products, the regulations, and the risks so you can make an informed decision.
What Is Compounded Semaglutide and How Is It Different from Ozempic?
Ozempic and Wegovy are brand-name semaglutide products manufactured by Novo Nordisk. They go through the full FDA approval process: large-scale clinical trials, manufacturing inspections, batch-by-batch quality testing, and post-market surveillance. Every vial or pen that reaches a patient has been produced under current Good Manufacturing Practice (cGMP) standards in facilities the FDA inspects regularly.
Compounded semaglutide is prepared by a compounding pharmacy, which purchases the raw active pharmaceutical ingredient (API) and formulates it into an injectable product. Compounding pharmacies are not required to conduct clinical trials. Their products are not FDA-approved. The legal basis for compounding exists to fill gaps: when a patient needs a specific dose, formulation, or combination that is not commercially available, or when an FDA-approved drug is in shortage.
This is an important distinction. Compounded semaglutide is not a generic. Generics go through an Abbreviated New Drug Application (ANDA) process and must demonstrate bioequivalence to the brand-name product. Compounded products have no such requirement.
What Is the Difference Between 503A and 503B Compounding Pharmacies?
This is the single most important regulatory distinction in this space, and most consumers do not know it exists. The Federal Food, Drug, and Cosmetic Act created two categories of compounding pharmacies after the 2012 New England Compounding Center meningitis outbreak that killed 76 people.
Section 503A pharmacies are traditional compounders. They prepare medications for individual patients based on a specific prescription. They are regulated primarily by state boards of pharmacy, not the FDA. They are not required to follow cGMP standards, are not routinely inspected by the FDA, and do not have to report adverse events to the FDA. Quality oversight varies enormously from state to state.
Section 503B outsourcing facilities are a newer category created by the Drug Quality and Security Act of 2013. They can produce compounded medications in larger batches without individual prescriptions. In exchange for that flexibility, they must register with the FDA, follow cGMP standards, be subject to FDA inspection, and report adverse events. They are, in effect, held to a standard much closer to (though not identical to) pharmaceutical manufacturers.
âšī¸You can verify whether a compounding pharmacy is a registered 503B outsourcing facility on the FDA's website. If a pharmacy claims to be 503B-registered but does not appear on the FDA's list, that is a significant red flag. The list is publicly searchable at fda.gov.
Why Does the Salt Form of Semaglutide Matter?
Novo Nordisk's approved products use semaglutide in its base form. Many compounding pharmacies have used semaglutide sodium or semaglutide acetate because these salt forms have been more readily available as raw API on the wholesale market. The FDA has stated that these are different substances and that compounding with semaglutide sodium does not qualify as compounding the same drug that is on the shortage list.
From a chemistry perspective, the salt form changes the molecular weight. Semaglutide base has a molecular weight of approximately 4,113.6 Da. Semaglutide sodium is heavier because of the sodium counterion. This means that 1 mg of semaglutide sodium contains less active semaglutide molecule than 1 mg of semaglutide base. If a compounder is not adjusting for this difference, the patient receives a lower effective dose than intended.
More importantly, no clinical trials have been conducted on semaglutide sodium or semaglutide acetate in humans. The pharmacokinetic profile (how the drug is absorbed, distributed, and eliminated) may differ. The FDA's position, stated in multiple warning letters issued in 2023 and 2024, is that products containing semaglutide salt forms are unapproved new drugs, not legally compounded versions of the approved product.
What Have Testing Studies Found in Compounded Semaglutide Products?
Several independent analyses have tested compounded semaglutide samples, and the results are concerning. A 2023 investigation by the FDA found that some tested samples contained no detectable semaglutide at all, while others contained incorrect amounts. The FDA issued public alerts about these findings.
A study published in JAMA Network Open in 2024 by Sodhi et al. analyzed compounded semaglutide products purchased from multiple online sources. Of the samples tested, significant variability was found in peptide content, with some samples containing substantially less active ingredient than labeled and others containing unidentified impurities. Bacterial endotoxin contamination was detected in a subset of samples, which is particularly dangerous in injectable products.
NBC News and other media outlets commissioned independent lab testing in 2024 and reported similar findings: inconsistent dosing, wrong compounds, and in some cases, products that appeared to contain research-grade peptides not suitable for human injection. These are not theoretical risks. They have been measured and documented.
- Underdosing: less active ingredient than the label states, meaning reduced or no clinical effect
- Overdosing: more active ingredient than labeled, increasing risk of severe nausea, vomiting, and hypoglycemia
- Wrong salt form: semaglutide sodium or acetate labeled as semaglutide, with unknown dose equivalency
- Bacterial endotoxins: pyrogen contamination that can cause fever, sepsis, and in severe cases, death
- Unidentified impurities: degradation products, synthesis byproducts, or entirely wrong compounds
- Sterility failures: inadequate aseptic technique leading to microbial contamination
What Has the FDA Actually Done About Compounded Semaglutide?
The FDA has taken several actions. Throughout 2023 and 2024, the agency issued warning letters to multiple compounding pharmacies for selling products containing semaglutide salt forms, making unapproved drug claims, and operating outside the legal scope of compounding exemptions. These warning letters are public and searchable on the FDA website.
In October 2024, the FDA announced that the semaglutide shortage had been resolved, which removed the legal basis under which many 503A pharmacies were compounding the drug. The agency subsequently pursued enforcement actions against pharmacies that continued compounding after the shortage resolution. Some pharmacies challenged these actions in court, and as of early 2026, litigation continues on several fronts regarding the scope of compounding rights.
It is worth noting that the FDA has limited enforcement resources. The number of entities selling compounded peptides online far exceeds the agency's capacity to inspect and enforce against all of them. Warning letters represent a fraction of the market. The absence of a warning letter does not indicate FDA approval or compliance.
â ī¸The legal status of compounded semaglutide has been shifting and may continue to change. What was legally available during the shortage period may not be legal after the shortage resolution. If you are currently using a compounded product, check whether your pharmacy is operating under current legal authority, not the authority that existed when you first started.
What About Other Peptides Sold Online (BPC-157, AOD-9604, and Others)?
The market for non-GLP-1 peptides is even less regulated. Compounds like BPC-157, AOD-9604, GHK-Cu, and others are widely sold through online "peptide clinics" and direct-to-consumer websites. Most of these peptides have not been approved by the FDA for any indication. Many have limited or no human clinical trial data.
The sourcing of these peptides is often opaque. Many originate from overseas synthesis labs (primarily in China) and are imported as research chemicals. Repackaging research-grade peptides for human injection is not legal, but enforcement is sporadic. Quality control at the synthesis level varies enormously. Without a certificate of analysis from an independent, accredited lab (not the seller's own lab), you have no reliable information about what is actually in the vial.
In 2023, the FDA specifically added BPC-157 and several other peptides to its list of "Category 2" substances that cannot legally be compounded under 503A or 503B exemptions, citing insufficient safety data. This means that any pharmacy selling injectable BPC-157 as a compounded drug is operating outside federal law, regardless of what a prescriber writes on a prescription.
How Do You Evaluate an Online Pharmacy Selling Peptides?
There is no foolproof method, but there are red flags and green flags. No evaluation can guarantee product safety, but these checks can help you filter out the most obvious risks.
- Check 503B registration: verify the pharmacy appears on the FDA's outsourcing facility registry. This is the single strongest indicator of regulatory oversight.
- State licensing: confirm the pharmacy holds a valid license in its operating state and in the state where you reside. State board of pharmacy websites are searchable.
- Third-party testing: ask whether the pharmacy uses independent, accredited labs for potency and sterility testing, and whether certificates of analysis are available. If they refuse or cannot provide them, that is telling.
- Prescriber requirement: legitimate pharmacies require a prescription from a licensed provider. If you can order without a prescription, the operation is almost certainly not compliant.
- Beyond-use dating: compounded injectables have shorter shelf lives than manufactured drugs. Ask about beyond-use dates. If the pharmacy claims multi-year expiration on a compounded injectable, be skeptical.
- Price that seems too good: compounding semaglutide properly (sourcing pharmaceutical-grade API, sterility testing, proper formulation) is not cheap. Prices dramatically below the market average may reflect corners being cut on quality control.
đĄThe Pharmacy Compounding Accreditation Board (PCAB) offers voluntary accreditation for compounding pharmacies. PCAB-accredited pharmacies have agreed to meet quality standards beyond state minimums. It is not a guarantee, but it is one additional data point.
What Should You Do If You Have Side Effects from a Compounded Product?
Report them. The FDA's MedWatch system (fda.gov/medwatch) accepts voluntary reports from consumers and healthcare providers. These reports are one of the few tools the FDA has for tracking adverse events from compounded products, because compounders (unlike manufacturers) are not always required to report. Your report contributes to the evidence base that informs enforcement decisions.
Tell your prescriber. If you are working with a telehealth provider who prescribed the compounded product, document your symptoms and communicate them clearly. Tools like GLP1Gut can help you track GI symptoms, timing, and severity patterns so you have concrete data to share rather than relying on memory. If you experience a serious adverse event (hospitalization, life-threatening symptoms, or persistent disability), that report is especially important.
If you suspect you received a contaminated or mislabeled product, you can also file a report with your state board of pharmacy. State boards have direct enforcement authority over 503A pharmacies operating within their borders.
Is Compounded Semaglutide Ever a Reasonable Choice?
This article is not going to make that decision for you, because the answer depends on factors that are specific to your situation: your insurance coverage, your access to brand-name medications, your risk tolerance, and the specific pharmacy you are considering. What we can say is that the risk profile is not zero, and it is not fully characterized.
Some patients have used compounded semaglutide from reputable 503B facilities during the shortage period and had positive experiences. Others have been hospitalized from contaminated products. The difference almost always comes down to the specific pharmacy, its quality control processes, and the regulatory framework it operates under.
If cost is the primary barrier to brand-name access, it is worth exploring Novo Nordisk's patient assistance programs, manufacturer savings cards, and whether your insurance plan covers any GLP-1 medications. These options do not work for everyone, but they are worth exhausting before turning to the compounded market.
Is compounded semaglutide the same as generic semaglutide?
No. A generic drug must go through the FDA's ANDA process and demonstrate bioequivalence to the brand-name product. There is no FDA-approved generic semaglutide as of early 2026. Compounded semaglutide has not been tested for bioequivalence and is not subject to the same manufacturing standards.
Can my doctor legally prescribe compounded semaglutide?
The legality depends on whether the FDA-approved version is currently in shortage and whether the compounding pharmacy is operating under valid 503A or 503B authority. When semaglutide is not on the FDA shortage list, the legal basis for most compounding is significantly narrowed. Your prescriber should be aware of the current regulatory status.
What happens if I am currently using compounded semaglutide and the legal status changes?
Work with your prescriber to develop a transition plan. Options may include switching to brand-name medications if accessible, exploring patient assistance programs, or discussing alternative therapies. Do not abruptly stop a GLP-1 agonist without medical guidance, as rebound effects on appetite and blood sugar can occur.